Status:
UNKNOWN
Safety & Efficacy of Low Dose Aspirin / Ivermectin Combination Therapy for Treatment of Covid-19 Patients
Lead Sponsor:
Makerere University
Collaborating Sponsors:
Ministry of Health, Uganda
Mbarara University of Science and Technology
Conditions:
Covid19
Eligibility:
All Genders
18-64 years
Phase:
PHASE2
PHASE3
Brief Summary
COVID-19, caused by the novel Severe Acute Respiratory Syndrome Corona Virus 2 (SARSCoV-2), has become a global pandemic. Fortunately, most of the COVID-19 cases confirmed are categorized as mild for ...
Detailed Description
Micro clotting is to date reported as a major cause of death among COVID-19 patients. SARS-CoV-2 associated micro clotting results into acute respiratory distress syndrome (ARDS) and death. This micro...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Provision of signed and dated informed consent form
- Willingness to comply with all study procedures and availability over the study duration \*Patients aged above 18years to 64 years
- PCR positive for SARS-Cov-2 (COVID-19) from any of the MOH COVID-19 accredited testing laboratories
- Moderately ill COVID-19 patients score 3(Hospitalized with no oxygen therapy) to 4 (Hospitalized with oxygen by mask or nasal prongs) according to the WHO ordinal scale for clinical improvement which translates to moderate to severe COVID-19 patients according to the Ministry of Health Uganda COVID-19 disease category.
- Exclusion criteria:
- Participants with known hypersensitivity to Ivermectin
- Clinical diagnosis of severe renal and hepatic impairment.
- Pregnancy or breast feeding.
- Co-treatment with either strong cytochrome p-450 inducers including: rifampicin, carbamazepine and barbiturates or inhibitors: isoniazid, clofazimine that might potentially affected ivermectin disposition and clinical outcomes
- Co-morbidities including asthma
- Loa loa as assessed by travel history to Angola, Cameroon, Chad, Central African Republic, Congo, DR Congo, Equatorial Guinea, Ethiopia, Gabon, Nigeria and Sudan in the last 4 years
- Persons clinically diagnosed with and receiving treatment for any diathesis and PUD
- Active participation in another clinical trial
Exclusion
Key Trial Info
Start Date :
February 19 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2021
Estimated Enrollment :
490 Patients enrolled
Trial Details
Trial ID
NCT04768179
Start Date
February 19 2021
End Date
September 30 2021
Last Update
February 24 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.